These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15146205)

  • 1. [Active immunotherapy in the treatment of haematological neoplasias].
    Inogés S; Rodríguez Calvillo M; López Díaz de Cerio A; Zabalegui N; Melero I; Sánchez Ibarrola A; Rocha E; Bendandi M
    An Sist Sanit Navar; 2004; 27(1):45-62. PubMed ID: 15146205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active immunotherapy in follicular lymphoma.
    Veelken H
    Semin Cancer Biol; 2003 Jun; 13(3):241-7. PubMed ID: 12959355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Idiotype vaccines in the treatment of follicular lymphoma: current status and future perspectives].
    Zabalegui N; López Díaz de Cerio A; Inogés S; Soria E; Villanueva H; Rivero P
    An Sist Sanit Navar; 2009; 32(1):61-73. PubMed ID: 19430512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active immunotherapy of multiple myeloma.
    Houet L; Veelken H
    Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priming anticancer active specific immunotherapy with dendritic cells.
    Mocellin S
    Curr Opin Investig Drugs; 2005 Jun; 6(6):576-81. PubMed ID: 15988908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: cancer immunotherapy by exosome-based vaccines.
    Hao S; Moyana T; Xiang J
    Cancer Biother Radiopharm; 2007 Oct; 22(5):692-703. PubMed ID: 17979572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR
    Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic vaccines for prostate cancer: a review of clinical data.
    Arlen PM; Gulley JL
    Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting dendritic cells for active immunotherapy of cancer and chronic infections.
    O'Neill DW; Bhardwaj N
    Mol Biotechnol; 2007 Jun; 36(2):131-41. PubMed ID: 17914192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active and passive immunotherapy: vaccines and antibodies.
    Oosterwijk E; Divgi C; Bander NH
    BJU Int; 2007 May; 99(5 Pt B):1301-4. PubMed ID: 17441928
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.
    Alberti C
    G Chir; 2017; 37(5):225-235. PubMed ID: 28098061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
    Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
    J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cancer immunotherapy--current status].
    Kundig TM; Renner Ch; Knuth A
    Ther Umsch; 2006 Apr; 63(4):262-6. PubMed ID: 16689457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
    Vose J
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing dendritic cell-based immunotherapy for cancer.
    Zhong H; Shurin MR; Han B
    Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-Based Immunotherapy of Gliomas.
    Everson RG; Antonios JP; Liau LM
    Prog Neurol Surg; 2018; 32():90-100. PubMed ID: 29990977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic approaches for the treatment of malignant melanoma.
    Curiel-Lewandrowski C; Atkins MB
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1553-63. PubMed ID: 11763157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Active immunotherapy of prostate cancer with a focus on dendritic cells].
    Thomas-Kaskel AK; Veelken H
    Actas Urol Esp; 2007 Jun; 31(6):668-79. PubMed ID: 17896564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.